-+ 0.00%
-+ 0.00%
-+ 0.00%

Jasper Therapeutics Q3 EPS $(10.19) Misses $(4.80) Estimate, Sales $8.000M Beat $3.000M Estimate

Benzinga·11/16/2026 13:49:17
Listen to the news
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(10.19) per share which missed the analyst consensus estimate of $(4.80) by 112.29 percent. This is a 68.24 percent increase over losses of $(32.08) per share from the same period last year. The company reported quarterly sales of $8.000 million which beat the analyst consensus estimate of $3.000 million by 166.67 percent.